For example, the pan-PI3K inhibitor buparisib (BKM120) has shown antitumor activity in estrogen receptor (ER) positive breast cancer and xenograft tumors, either alone or in combination, and has been studied in phase III clinical trials in breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.